The results of a new study by the Pathology work package were presented at the annual meeting of the Norwegian Pathology Society. The study shows that pathology evaluation of the effect of neoadjuvant treatment of pancreatic cancer, is only reliable if tumour regression is extensive, while lesser degrees of treatment effect cannot be identified with certainty. Maia Blomhoff Holm (to the right on the photograph), who presented the study, was awarded the “Research prize 2024 – best free paper”. Read the publication